STEAP4 and neoplasm: Subsequent studies should evaluate the efficacy of NQO1 bioactivatable drugs, such as β-LPC and KP372-1, in selectively targeting tumor cells with high STEAP4 expression using patient-derived models and mouse models (Kim et al., 2023).